Open Access

Glucose-Regulated Protein 78 Autoantibodies Are Associated with Carotid Atherosclerosis in Chronic Obstructive Pulmonary Disease Patients

Thi K. Tran-Nguyen, Divay Chandra, Kaiyu Yuan, Phani K. Patibandla, Khanh T. Nguyen, Palaniappan Sethu, Yingze Zhang, Jianmin Xue, James A. Mobley, Young-il Kim, Ali Shoushtari, Joseph K. Leader, Jessica Bon, Frank C. Sciurba and Steven R. Duncan
ImmunoHorizons February 1, 2020, 4 (2) 108-118; DOI: https://doi.org/10.4049/immunohorizons.1900098

Abstract

Atherosclerosis prevalence is increased in chronic obstructive pulmonary disease (COPD) patients, independent of other risk factors. The etiology of the excess vascular disease in COPD is unknown, although it is presumably related to an underlying (if cryptic) systemic immune response. Autoantibodies with specificity for glucose-regulated protein 78 (GRP78), a multifunctional component of the unfolded protein response, are common in COPD patients and linked to comorbidities of this lung disease. We hypothesized anti-GRP78 autoreactivity might also be a risk factor for atherosclerosis in COPD patients. Carotid intima-medial thickness (cIMT) was measured in 144 current and former smokers by ultrasound. Concentrations of circulating IgG autoantibodies against full-length GRP78, determined by ELISA, were greater among subjects with abnormally increased cIMT (p < 0.01). Plasma levels of autoantibodies against a singular GRP78 peptide segment, amino acids 246–260 (anti-GRP78aa 246–260), were even more highly correlated with cIMT, especially among males with greater than or equal to moderate COPD (rs = 0.62, p = 0.001). Anti-GRP78aa 246–260 concentrations were independent of CRP, IL-6, and TNF-α levels. GRP78 autoantigen expression was upregulated among human aortic endothelial cells (HAECs) stressed by incubation with tunicamycin (an unfolded protein response inducer) or exposure to culture media flow disturbances. Autoantibodies against GRP78aa 246–260, isolated from patient plasma by immunoprecipitation, induced HAEC production of proatherosclerotic mediators, including IL-8. In conclusion, anti-GRP78 autoantibodies are highly associated with carotid atherosclerosis in COPD patients and exert atherogenic effects on HAECs. These data implicate Ag-specific autoimmunity in the pathogenesis of atherosclerosis among COPD patients and raise possibilities that directed autoantibody reduction might ameliorate vascular disease in this high-risk population.

Introduction

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United Stated (1). Although the respiratory abnormalities of COPD result in considerable morbidity and mortality, the majority of deaths among these patients are due to atherosclerotic cardiovascular disease (CVD) (2–5). The increased prevalence of atherosclerosis in COPD is not fully explained by smoking exposure, age, hypertension, and other established CVD risks (6, 7). Chronic inflammation has been implicated in the development of atherosclerosis in COPD patients, although the nature of the causal immunological mechanism(s) remains unknown (4, 8).

We, and others, have shown that autoimmunity can mediate chronic inflammation in COPD (9–11). IgG autoantibodies with diverse specificities and effects are frequently present and associated with immune complex deposition and complement activation in the diseased lungs of COPD patients (9–12). B cell aggregates in nonlymphoid organs are a pathognomonic feature of chronic immune responses that exert numerous pathological effects, in addition to their production of Abs (13), and these are also a common finding in COPD lungs (14). B cells infiltrate into diseased tissues because of the local production of chemotactic factor C-X-C chemokine 13 (CXCL13), and this trafficking mediator is overexpressed in COPD lungs (15). Circulating concentrations of BAFF (also known as BLyS), a trophic factor for B cell survival and function, are also increased proportionately to disease severity among patients with conventional autoimmune syndromes as well as those with COPD (16).

IgG autoantibodies with avidity for glucose-regulated protein 78 (GRP78) are present in many COPD patients (12). GRP78 is a multifunctional endoplasmic reticulum (ER) stress and heat shock protein (HSP) that plays an important role in the unfolded protein response (UPR) (17, 18). Pulmonary GRP78 production is increased by various stresses, and high levels of this protein are expressed in COPD lungs (12, 19). In addition to its intracellular localization and functions, GRP78 can also be exported into extracellular spaces, whereupon it acts as a cytokine by cognate binding to specific cell surface receptors that transduce danger signals (18). Anti-GRP78 Abs can cross-link and enhance the signaling events mediated by these GRP78-receptor complexes, resulting in significant alterations of several diverse cellular functions (12, 20–22).

Because anti-GRP78 autoantibodies are common in COPD patients, and have myriad potentially injurious effects (12, 20–22), we hypothesized that the “spillover” of these autoantibodies from their putative origin in injured lungs (14, 15) might also be involved in vascular pathogenesis. We tested our hypothesis by examining the association in COPD patients of circulating anti-GRP78 autoantibodies with carotid intima-medial thickness (cIMT), a facile correlate of systemic atherosclerotic disease (23). Additional studies looked for expression of GRP78 among human aortic endothelial cells (HAECs), surveyed for differences of epitope(s) specificity among the autoantibodies most highly associated with cIMT abnormalities, and sought to determine if patient-derived anti-GRP78 autoantibodies can deleteriously alter HAEC functions.

Materials and Methods

Study participants

Subjects were enrolled from the Pittsburgh COPD Specialized Center for Clinically Oriented Research cohort. This population consists of 40- to 79-y-olds with minimum 10 pack-year smoking histories and excluded participants with other significant lung diseases, vascular or cardiac events in the preceding year, prior thoracic surgery, or a body mass index >35 kg/m2. Each subject completed demographic and medical history questionnaires, pulmonary function tests (PFT), chest computed tomography (CT) examinations, carotid ultrasounds, and blood sample collection. Written informed consent was obtained from each participant.

This study was approved by the Institutional Review Boards at the University of Pittsburgh and University of Alabama at Birmingham.

Lung assessments

Results of pulmonary function tests were adjusted to standard population-derived predicted values (24). COPD was defined by the presence of fixed expiratory airflow obstruction, (i.e., a ratio of the forced expiratory volume in 1 s [FEV1] to forced vital capacity [FVC] [FEV1/FVC] <0.70) (24). Subjects with COPD were further classified by severity according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, which are based on percent predicted (pp) FEV1: GOLD 1 = FEV1pp >80%; GOLD 2 = >50% FEV1pp <80%; GOLD 3 = >30% FEV1pp <50%; and GOLD 4 = FEV1pp <30% (24).

Chest CT scans were performed with a LightSpeed VCT 64-Detector Scanner (GE Healthcare, Little Chalfont, United Kingdom) without i.v. contrast and quantified as detailed previously (25). Briefly, the extent of emphysema (defined as parenchymal lung loss) was calculated by traditional density mask analyses on inspiratory CT scans as the percentages of total lung volume with attenuation ≤−950 Hounsfield units (F950). The presence of emphysema was defined as F950 >0.05 (26).

Carotid ultrasounds

Carotid artery ultrasound studies were performed in consecutively recruited subjects using a GE 9L Linear Array Transducer with a frequency of 3–10 MHz (GE Healthcare, Tokyo, Japan) and GE Vivid 7 Dimension Ultrasound (GE Vingmed Ultrasound, Horten, Norway). Intima-media thickness was measured using automated edge detection software that located the lumen-intima and media-adventitia echo boundaries at subpixel resolution and made >50 measurement of the intima-media thickness along a 1-cm segment of the distal common carotid artery 1 cm proximal from the carotid bifurcation at end-diastole. These >50 measurements were averaged to calculate the intima-media thickness for each side, and the mean of the values from the left and right carotid was used for data analyses. cIMT ≥0.9 mm were classified as abnormal.

Autoantigen discovery

The nonbiased methods that resulted in discovery of GRP78 autoimmunity in COPD have been previously detailed (12).

Anti-GRP78 autoantibody assays

Full-length human GRP78 was cloned into the pDB-HisGST vector (DNASU plasmid repository, Arizona State University, Tempe, AZ) containing the N-terminal 6*His-tag. The protein was overexpressed in Escherichia coli strain BL21(DE3) (Thermo Fisher Scientific, Waltham, MA) that was propagated in Luria-Bertani medium. After lysis and centrifugation, the recombinant GRP78 (rGRP78) was purified on nickel columns.

rGRP78 was used as the substrate of ELISA by dilution to 0.5 μg/ml in PBS prior to incubation in ELISA plate wells (100 μl/well) overnight at 4°C. After thorough washing and blocking, plasma specimens were added to the wells at 1:100 dilutions and incubated for 2 h. Following additional washes, alkaline phosphatase (AP)–conjugated goat anti-human Ab (Invitrogen, Carlsbad, CA) at 1:5000 dilution was added and color developed with a pNPP substrate system (Kirkegaard & Perry Lab, Gaithersburg, MD). ODs were determined at 405 nm.

Inflammatory mediators

High-sensitivity CRP (hs-CRP) was measured in plasma samples using an ultrasensitive electrochemiluminescence immunoassay according to the manufacture’s protocol (Meso Scale Discovery, Gaithersburg, MD).

IL-6 and TNF-α levels were measured using ELISA kits according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).

Cardiovascular risk covariates

Hypertension was defined as systolic blood pressure >140 mm Hg measured during the study visit or use of an antihypertensive medication. Hyperlipidemia and diabetes were defined by the use of a lipid-lowering or diabetic medication, respectively, or patient reports of these diagnoses. Family histories of vascular disease were established by patient report.

HAECs

HAECs were purchased (Invitrogen) and expanded in Medium 200 with low-serum growth supplement from the same supplier, 5% FBS, and 1% penicillin-streptomycin. Standard plastic tissue culture flasks were coated with 5 μg/ml fibronectin (Sigma-Aldrich, St. Louis, MO) for 2 h at 37°C, before seeding with HAECs. HAECs were detached from cultures at ∼70% confluency with 0.05% trypsin/0.53 mM EDTA for subsequent plating.

Microfluidic endothelial cell culture model

HAECs were cultured within the endothelial cell culture model (ECCM) and subjected to either normal pulsatile flow (as seen in linear arterial sections) or oscillatory-disturbed flow associated with atherosclerosis-susceptible regions (e.g., arterial bifurcations) using cell culture chambers and flow loops that have been previously detailed (27). After culture within the ECCM for 24 h, the HAECs were washed with cold PBS, then fixed on the polymeric membranes with 4% paraformaldehyde for immunofluorescence imaging (27).

Immunofluorescence staining and confocal microscopy

Fixed HAECs on ECCM polymeric membranes were washed with PBS, blocked with 5% BSA at room temperature for 30 min, and incubated overnight at 4°C with anti-GRP78 Ab (cat# sc-1051; Santa Cruz Biotechnology, Dallas, TX) or normal goat IgG as isotype control (cat# sc-2020; Santa Cruz Biotechnology), both of which were diluted 1:50 in 1% BSA in PBS. Membranes were again washed three times with PBS, 5 min each, prior to incubation with a 1:5000 dilution of anti-goat F(ab′)2 conjugated to Texas Red (cat# NB120-6523; Novus Biologicals, Centennial, CO). Stained membranes were air-dried before adding mounting solution with DAPI (Vector Laboratories, Burlingame, CA).

Images were captured using an A1R confocal microscope (Nikon Instruments, Melville, NY).

Flow cytometry to assess GRP78 expression on HAECs

HAECs were treated with tunicamycin (2.5 μg/ml; MilliporeSigma, Burlington, MA), an inducer of ER stress, or DMSO (solvent control), also at 2.5 μg/ml, in Medium 200 for 48 h. Cells were collected by scraping and then washed one time with FACS buffer (HBSS + 0.1% BSA + 0.1% sodium azide) before being incubated with 0.5 μg in 50 μl of FACS buffer of either GRP78 rabbit polyclonal Ab (cat# 3183S; Cell Signaling Technology, Beverly, MA) or isotype control (cat# 02-61020; Thermo Fisher Scientific) for 25 min on ice. Cells were then washed one time before incubation with anti-rabbit IgG (H+L) F(ab′)2 fragments (PE-conjugated), at 1:500 dilution in FACS buffer for another 25 min. 7-AAD was added as the final step.

Data were acquired on a BD LSR-II Cytometer (BD Biosciences, San Jose, CA) and analyzed by FlowJo software (FlowJo, Ashland, OR).

GRP78 peptides

Potential linear epitopes of GRP78 (8–20 aa in length) were identified in silico using the BepiPhred-2.0 sequential B cell-epitope predictor (http://www.cbs.dtu.dk/services/BepiPred/). The corresponding peptides were synthesized by Thermo Fisher Scientific and are listed in Supplemental Table I. Each peptide was biotinylated at the N terminus, after addition of an aminohexanoic (Ahx) linker, to minimize steric hindrance. The identity and purity of these synthesized peptides were confirmed by mass spectrometry.

For use in ELISA, the biotinylated peptides were diluted to 0.5 μg/ml in PBS and added to wells of a streptavidin-coated microplate (R&D Systems) for overnight incubation at 4°C. Subsequent steps were identical to those described for full-length rGRP78 ELISA (above).

Isolation of anti-GRP78aa 246–260 autoantibodies

IgG in pooled plasma from COPD patients was precipitated by ammonium sulfate, resuspended, dialyzed, and then captured on protein G columns (Life Technologies, Carlsbad, CA) (12). After several column-volume washes, the IgG was eluted with 100 mM glycine (pH 3.0) and the eluant pH neutralized with Tris buffer. IgG in this solution was concentrated using 50-kDa centrifugal filters and measured by spectrophotometer. Control IgG was obtained by identical isolations from pooled normal plasma specimens. The IgG identity of both preparations was confirmed by SDS gel electrophoresis.

Autoantibodies with specificity for GRP78aa 246–260 were isolated from the COPD IgG by immunoprecipitation. Synthesized, biotinylated GRP78aa 246–260 peptide was coupled to streptavidin agarose resin columns, following the manufacturer’s instructions (Thermo Fisher Scientific). The columns were repeatedly washed with PBS and then incubated with the COPD IgG overnight at 4°C. After another exhaustive washing, anti-GRP78aa 246–260 autoantibody was eluted with acidified buffer, neutralized, and concentrated using centrifugal filters. The purity and avidity of anti-GRP78aa 246–260 autoantibody were confirmed by SDS gel electrophoresis and Western blots against denatured rGRP78. The Ab was diluted with complete media and sterile-filtered before incubation with HAECs. Endotoxin concentrations in these autoantibody preparations were below the detection threshold of a Pierce LAL Chromogenic Endotoxin Quantitation Kit (Pierce Biotechnology, Rockford, IL).

IgG purified by protein G from pooled normal human serum (cat# I4506; Sigma-Aldrich) was used as the control for the GRP78aa 246–260. This control IgG preparation was also subjected to the same incubations with agarose resin columns, washes, elutions, and endotoxin assays as the GRP78aa 246–260 IgG.

HAEC treatment with anti-GRP78aa 246–260 autoantibodies

HAECs (2 × 105/ml) were seeded in 12 well-plates that had been previously coated with fibronectin (5 μg/ml). After 2 d of culture, the HAECs were incubated with either anti-GRP78aa 246–260 IgG or control IgG (each at 5 μg/ml) for 8 h before harvesting for RNA extraction. Supernatants were collected from otherwise identically treated HAEC culture after 24 h for ELISA assays.

RNA isolation and NanoString analyses

Harvested HAECs were washed and lysed, and RNA was isolated using the reagents and procedures supplied in a kit (RNAeasy Plus; Qiagen, Hilden, Germany). RNA quality was confirmed, and concentrations were determined by nanodrop.

The RNA was cleaned and concentrated using a kit (Zymo Research, Irvine, CA) and eluted in RNase-free water. One hundred nanograms was added to the Reporter CodeSet and Capture ProbeSet of the premade Human Inflammation Panel (NanoString Technologies, Seattle, WA) and hybridized overnight at 65°C, per the manufacturer’s protocol. Samples were subsequently processed on a NanoString Technologies Prep station and Digital Analyzer, and the data were analyzed with this company’s nSolver 4.0 Software. Volcano plots were generated by using R version 3.5.0. with packages ggplot2, dplyr, and ggrepel.

Quantitative real-time RT-PCR

cDNA from the HAEC RNA aliquots were synthesized using SuperScript IV First-Strand Synthesis System (Invitrogen). Quantitative real-time RT-PCR, used to confirm selected NanoString findings, was performed on this cDNA using iQTM SYBER Green Supermix (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s recommendation. The primers used in these reactions were produced by Integrated DNA Technologies (Skokie, IL) and included IL-8 forward (5′-GACCACACTGCGCCAACAC-3′) and reverse (5′-CTTCTCCA CAACCCTCTGCAC-3′) and IFN regulatory factor-7 (IRF-7) forward (5′-ACCCTGG CTGTGCCGAGT-3′) and reverse (5′-AAGCACTCGATGTCGTCATAGAG-3′). GAPDH primers were purchased from Bio-Rad Laboratories. Reactions were performed in triplicate and normalized to GAPDH using the comparative 2−ΔΔCT method (28).

ELISA for IL-8

HAECs culture supernatants collected at 24 h after IgG stimulation were used to measure IL-8 concentrations by ELISA (R&D Systems). Standard curves and concentrations were calculated by using the 4PL curve-fit method with online software (https://mycurvefit.com/).

Statistical analyses

Continuous or ordered variables were compared using the Kruskal–Wallis test. Dichotomous variables were compared by χ2. Spearman rank-order correlations were used to identify associations between continuous or ordinal variables. Multivariable logistic regression models were constructed to identify variables, which predict abnormal cIMT, and to control various covariates and potential confounders. The Wald test was used to identify variables that significantly explain the abnormal cIMT outcome.

Analyses were performed using Prism software, version 5.0b. Summary statistics are reported as medians, ranges or means ± SD for continuous variables, and proportions (%) for categorical variables. Statistical significance was defined as two-tailed p < 0.05.

Results

Subjects

The study cohort was composed of 144 consecutive Specialized Center for Clinically Oriented Research participants who had both anti-GRP78 IgG measurements and carotid ultrasounds. Eighty-one of these subjects had normal spirometry, despite extensive smoking histories (smoke controls [SC]), and 63 had COPD. There were no attempts to select participants based on gender, or other demographic or clinical features, but fortuitously equal numbers of males and females were recruited (e.g., n = 72). Clinical and demographic characteristics of these populations are delineated in Table I.

View this table:
Table I. Characteristics of the study participants

Autoantibodies against full-length GRP78

Levels of circulating IgG autoantibodies to full-length rGRP78 did not differ between COPD and SC (Table I). However, autoantibody concentrations were significantly greater among the 64 subjects with carotid artery disease, defined as cIMT ≥0.9 mm, in comparison with the 80 subjects with normal cIMT (1.2 ± 0.4 versus 1.0 ± 0.4 OD units, p = 0.003) (Fig. 1A) and were weakly correlated with their cIMT values (Fig. 1B).

FIGURE 1.
FIGURE 1.

Autoantibodies to full-length GRP78 protein in the study cohort were associated with carotid atherosclerosis.

(A) Anti-GRP78 autoantibody levels (as ODs measured by ELISA) were greater in the subpopulation with abnormal cIMT, defined by cIMT ≥0.9 mm, compared with those with normal cIMT values. The lowest, second lowest, middle, second highest, and highest lines represent the 10th, 25th, median, 75th, and 90th percentiles, respectively. Means are denoted by the plus sign (+). (B) Correlation between the ELISA OD for autoantibodies with specificities to full-length GRP78 and cIMT in the aggregate study population. (C) Correlation between the levels of autoantibodies to full-length GRP78 and cIMT in male subjects. (D) Correlation between the levels of autoantibodies to full-length GRP78 and cIMT in males with COPD.

Although anti-GRP78 autoantibody levels were near identical in both male and female participants (1.1 ± 0.4 OD units in each), the clinical phenotype associations with anti-GRP78 autoreactivity have been previously reported to be gender biased (12). Accordingly, we performed post hoc analyses and found the association of anti-GRP78 to cIMT was greatest among male subjects (Fig. 1C), whereas this relationship was NS among females (rs = 0.08, p = 0.52). This autoantibody-cIMT association was stronger still in the males with COPD (Fig. 1D), compared with the COPD females (rs = −0.02, p = 0.93).

Autoantibodies against GRP78aa 246–260

To determine if one or more GRP78 autoantibody epitopes were singularly associated with cIMT abnormalities, we conducted a series of ELISA using linear, internal GRP78 peptides as the plate-bound ligands. Autoantibodies with avidities for one of these peptides, a 15-mer (ATNGDTHLGGEDFDQ), corresponding to GRP78 amino acid 246–260 (https://www.uniprot.org/uniprot/P11021), had the greatest association with cIMT within the aggregate study population (rs = 0.23, p < 0.01) compared with results with the other peptide ligands (Supplemental Table II) or with full-length rGRP78 (Fig. 1B). The unique specificity of anti-GRP78aa 246–260 may also be substantiated by finding a poor correlation between levels of this autoantibody and the anti–full-length rGRP78 (rs = 0.13, p = 0.13).

Circulating anti-GRP78aa 246–260 levels were near identical among males and females (0.27 ± 0.10 OD units each). Study participants with abnormal cIMT also had higher anti-GRP78aa 246–260 autoantibody concentrations compared with those with normal cIMT (Fig. 2A). Autoantibodies against this internal epitope were slightly, but significantly, greater among COPD patients compared with SC (Fig. 2B). The correlation between values for anti-GRP78aa 246–260 and cIMT was, again, strongest in the COPD patients, particularly among those with ≥GOLD 2 severity (Fig. 2C), and among the males within this disease subpopulation (Fig. 2D).

FIGURE 2.
FIGURE 2.

Autoantibodies to GRP78aa 246–260 peptide were even more related to measures of carotid artery disease.

(A) Circulating IgG autoantibodies to GRP78aa 246–260 peptide (as OD measured by ELISA) were higher in the population with abnormal cIMT (≥0.9 mm), compared with those with normal cIMT. The lowest, second lowest, middle, second highest, and highest lines represent the 10th, 25th, median, 75th, and 90th percentiles, respectively. Means are denoted by the plus sign (+). (B) Anti-GRP78aa 246–260 autoantibodies were increased in COPD patients compared with SC. (C) Correlation between levels of anti-GRP78aa 246–260 autoantibodies and cIMT among patients with moderate to advanced COPD (GOLD ≥2) (24). (D) Correlation between anti-GRP78aa 246–260 autoantibodies and cIMT among males with COPD GOLD ≥2.

These autoantibody-cIMT associations appeared to be independent of nonspecific inflammatory mediators, given the absence of any correlations between anti-GRP78aa 246–260 autoantibody levels and hs-CRP, IL-6, or TNF-α (Supplemental Fig. 1).

Logistic regression was used to model the relationship between anti-GRP78aa 246–260 autoantibody levels and the development of carotid atherosclerosis (defined as cIMT ≥0.9 mm). In the single independent variable (unadjusted) model, the odds ratio (OR) for an abnormal cIMT is 2.07 (95% confidence interval [CI] = 1.08–3.96) per each increase of anti-GRP78aa 246–260 autoantibodies by 0.1 OD unit (Fig. 3A). The cIMT-autoantibody association remained significant (OR = 2.6, 95% CI = 1.3–5.6) after adjusting for potentially confounding subject characteristics and other CVD risk factors, such as gender, current smoking status, pack years, FEV1pp, and the presence of other chronic diseases associated with atherosclerosis (Fig. 3B). Similarly, the association between anti-GRP78aa 246–260 autoantibody levels and abnormal cIMT still remained significant after including other, albeit nonspecific, inflammatory mediators such as IL-6, TNF-α, and hs-CRP independent variables in the logistic regression model (Fig. 3C–E).

FIGURE 3.
FIGURE 3.

Logistic models to predict the relationships of anti-GRP78aa 246–260 autoantibodies with the presence of abnormal cIMT (≥0.9 mm).

(A) Unadjusted model shows the OR of having an abnormal cIMT per an increase in 0.1 OD of anti-GRP78aa 246–260 autoantibodies. (B) Model 2 has been adjusted by gender, current smoking status, pack years, FEV1pp, and the presence of other chronic diseases associated with atherosclerosis (hypertension, diabetes, and hyperlipidemia). (C) Model 3 has been adjusted to include all the variables in model 2, plus the addition of circulating IL-6 (picograms per milliliter). (D) Model 4 has been adjusted to all the variables in model 2, with the addition of TNF-α (picograms per milliliter). (E) Model 5 has been adjusted to all the variables in model 2, with the addition of hs-CRP level (micrograms per milliliter). Bars denote 95% CI.

HAEC expression of GRP78

To establish that the GRP78 autoantigen is present among HAEC, and to explore conditions that might modify production of this autoantigen, we examined GRP78 expression in vascular cells exposed to various stresses.

A microfluidic device (27) was used to examine effects of altering culture media flow conditions (Fig. 4A, 4B) on GRP78 expression. Confocal microscopy showed that GRP78 expression was limited among HAECs cultured in conditions of normal pulsatile flow, whereas this autoantigen was significantly increased by stresses imposed by disturbed flow, as seen at arterial bifurcations (Fig. 4C–E) (27).

FIGURE 4.
FIGURE 4.

GRP78 expression on HAECs exposed to stresses of disturbed media flow and UPR induction.

Shear stress patterns of normal pulsatile flow (A) or disturbed flow (B) generated inside the microfluidic ECCM chamber (27). Confocal microscopy showed that GRP78 (red stain) on HAECs grown under conditions of normal pulsatile flow was limited (C), in contrast to GRP78 expression on HAECs subjected to stressful conditions that mimic disturbed fluid flows (D) as seen in vascular niches where atherosclerotic plaques tend to develop. Blue stain denotes DAPI. (E) Normal goat IgG (isotype control) followed by the same secondary Abs as in (C) and (D) [anti-goat F(ab')2-Texas Red] show the GRP78 staining of the latter is specific. (F) Tunicamycin (2.5 μg/ml) increased surface GRP78 expression on HAECs compared with DMSO (2.5 μg/ml) (carrier control) treatment.

HAECs incubated 48 h with tunicamycin, an inducer of the UPR and ER stressor, also exhibited increased surface expression of GRP78, compared with cells treated with DMSO control (Fig. 4F).

Potential pathogenic functions of anti-GRP78aa 246–260 autoantibodies

In addition to their widely known direct and indirect cytotoxic functions (13, 29, 30), IgG Abs can also evoke other, more specific, physiological effects, particularly if they bind to and cross-link cell surface receptors that transduce signals (12, 20–22, 31).

The potential functional effects of the anti-GRP78aa 246–260 autoantibodies that were most significantly related to cIMT in COPD patients (Fig. 2) were examined. We were especially interested in finding evidence that these autoantibodies directly exerted one or more clinically relevant pathological effects in HAECs.

Treatment of HAECs with anti-GRP78aa 246–260 altered a number of gene expressions, notably including (among other effects) increasing transcriptions of IL-8 and IRF-7 mRNA (Fig. 5A). These particular findings were further validated by quantitative RT-PCR (Fig. 5B, 5C) as well as ELISA to measure HAEC IL-8 chemokine secretion (Fig. 5D).

FIGURE 5.
FIGURE 5.

Anti-GRP78aa 246–260 autoantibodies altered HAEC gene expression.

(A) Volcano plot shows fold changes (log values) in levels of selected HAECs gene expressions, measured by NanoString assay (NanoString Human Inflammatory Panel), versus significance (p values), in HAECs treated with anti-GRP78aa 246–260 autoantibodies isolated from patient plasma. Changes are relative to measures in concurrent HAECs treated with normal IgG (n = 4 pairs). Validations of NanosString assay by RT-PCR confirmed IRF-7 mRNA (B) and IL-8 mRNA (C) were increased in HAECs by treatment with anti-GRP78aa 246–260 autoantibodies, again compared with cells treated with control IgG. (D) IL-8 concentrations, measured by ELISA, were greater in supernatants of HAECs treated with anti-GRP78aa 246–260 Abs compared with those treated with normal IgG control.

Discussion

These data show significant associations between anti-GRP78 IgG autoantibodies and carotid atherosclerosis in COPD patients. These relationships were strongest among males with moderate to severe expiratory airflow obstruction (Figs. 1, 2) who also happen to be the subpopulation of smokers at greatest risk for CVD. The increased risk of carotid abnormalities attributable to anti-GRP78 autoreactivity persisted despite adjustment for age, smoking extent, hypertension, diabetes, hyperlipidemia, or levels of CRP, IL-6, and TNF-α (Fig. 3). Several previous reports have described linkages between autoimmunity and atherosclerosis in other disease populations and animal models (32–34). Nonetheless, to our knowledge, this is the first study that has identified an Ag-specific adaptive immune response in COPD patients that is associated with atherosclerosis.

Several additional data in this study substantiate the biological plausibility and relevance of these findings. The development of autoimmunity is dependent on the accessibility of autoantigen(s) to immune effectors. GRP78 has been shown to be expressed by various cancer cells (18), leukocytes (12), and vascular endothelial cells activated by ER stress (22). The present studies confirm GRP78 expression is increased on HAECs during ER stress, as well as by culture in media subjected to disturbed flow, which replicates the physiological shear stresses these cells are exposed to in vascular bifurcations wherein atherosclerotic plaques preferentially develop (Fig. 4) (35). The overexpression of an otherwise nonimmunogenic self-protein is a risk factor for development of autoimmune responses to that protein, particularly if the overexpression is proximate to inflammatory foci (36–39). Intrapulmonary GRP78 levels are significantly increased in a number of inflammation-associated lung injuries, including noxious smoke exposure and COPD (12, 40).

Other mechanisms may also contribute to the induction of anti-GRP78 autoimmunity in COPD. Microbial colonization and/or infections are frequent (if not ubiquitous), in smoke-damaged lungs, are highly immunogenic, and are likely a predilection for subsequent development of autoimmunity against GRP78 and other HSP by epitope spread and mimicry (9, 41, 42). Increased local concentrations of HSP, including GRP78, that are proximate to injury foci may also promote “bystander” autoreactivity because of the close physical associations of these carrier molecules with foreign (e.g., microbial) Ags or other immunogenic proteins (43, 44). Covalent modifications of immunologically inert autologous proteins by highly reactive constituents of inhaled tobacco smoke can also result in generation of “neoantigens” that are no longer recognized as self (45, 46).

The data in this study also extend previous reports that have shown anti-GRP78 Abs can deleteriously alter functions of target cells, presumably by cross-linking the GRP78 bound to surface receptors (17, 20, 21, 31, 36). We recently found circulating anti-GRP78 IgG isolated from humans with COPD binds to monocyte-lineage cells and increases NF-κB phosphorylation and productions of IL-8, CCL2 (MCP-1), and MMP9 among those leukocytes (12). Another report showed autoantibodies raised in ApoE−/− mice by immunization with rGRP78 can induce expression of adhesion molecules (22). The present study shows that actual human in situ anti-GRP78aa 246–260 IgG autoantibodies, isolated directly from the plasma of COPD patients, are not only highly associated with cIMT (Fig. 2), but also have biologically relevant effects on vascular endothelial cells, which notably include inducing these cells to increase their productions of IL-8 and IRF-7 (Fig. 5). IL-8 causes rolling leukocytes to adhere to endothelial cells, is mitogenic and chemotactic for vascular smooth muscle cells, and is increased in unstable atherosclerotic plaques (47). IRF-7 acts as an integrative stress sensor that mediates signaling from pattern recognition receptors via MyD88 and, among other downstream effects, promotes the transcription of proatherosclerotic type I IFN (48).

To our knowledge, another novel finding of the current report is the discovery that carotid atherosclerosis in COPD patients seems to be especially associated with anti-GRP78 autoantibodies that have specificity for a distinct, internal GRP78 epitope (Fig. 2). The biological effects of various anti-GRP78 Abs seem to differ considerably, depending on the particular site of their binding: some anti-GRP78 autoantibodies stimulate certain target cell functions, whereas others that bind different regions of GRP78 are inhibitory (17, 31, 49). The present findings raise hopes that other anti-GRP78 autoantibodies could ameliorate or even counter deleterious effects of anti-GRP78aa 246–260, and a search for what could be “antiatherogenic” autoantibodies is ongoing. Incremental studies will also determine the clinical importance of cellular autoimmunity to GRP78aa 246–260 by testing the antigenicity of this peptide among T cells from COPD patients with and without cIMT abnormalities (12). Moreover, identification and subsequent use of the most clinically relevant linear peptide Ags in ELISA could obviate interassay variations of ligand binding because of the conformational variances of the larger, full-length rGRP78 molecule. The findings in this study that the cIMT association is stronger with anti-GRP78aa 246–260 (Fig. 2) than with the more complex admixture of autoantibodies against whole, intact GRP78 (Fig. 1) indicates the use of more-defined ligands will optimize the operating characteristics of these and related autoimmune assays.

Limitations of the current study include the use of a cohort that excluded subjects with recent cardiovascular events, those otherwise who would be at an increased risk because of morbid obesity, and all those with previous thoracic surgeries (e.g., coronary revascularization). Accordingly, the prevalence (and/or severity) of atherosclerosis in the subjects in this study is likely less than in unselected COPD patients. Because the operating characteristics of diagnostic assays are generally greatest in populations in which the disease prevalence (or severity) is highest (50), it is possible the clinical-immunological associations found in this study (Figs. 1, 2) may be even stronger in a general, unselected COPD population. Our vascular assessments were limited to carotid arteries, but the present findings almost certainly have general relevance for CVD in this patient population because carotid plaque assessment by ultrasound is a valid surrogate of coronary and other atherosclerotic abnormalities (23). We also did not thoroughly test for autoantibodies against conformational GRP78 epitopes, given the technical complexity of such studies, and those other anti-GRP78 Igs could additionally contribute to vascular disease.

Furthermore, the reductionist approach we employed in the current study to characterize unique characteristics of the anti-GRP78 IgG autoantibodies in COPD patients almost certainly underestimated the aggregate pathologic effects of these autoimmune responses in vivo. IgG autoantibodies are capable of forming complexes with Ag and activating complement, and these highly injurious processes, which also appear to be operative in COPD (9–12, 30), result in neutrophil recruitment to inflammatory foci and cytotoxicity of target cells (30). IgG binding to Fc receptors on granulocytes, phagocytes, NK cells, and B cells (among other subpopulations) can transduce signals that activate or otherwise deleteriously alter cell functions (29). Accordingly, we employed concurrent treatments with normal IgG as comparators to parse out effects of the anti-GRP78 IgG that are singularly attributable to their cognate specificity. Almost certainly, however, nonspecific binding of anti-GRP78 autoantibodies to cellular Fc receptors also has disease-relevant consequence in COPD patients. Moreover, autoantibody production against peptide autoantigens is typically dependent on help from T cells that share common Ag specificity, and the anti-GRP78 T cells that are present in COPD patients are also likely pathogenic (12) but were not examined in this study. Atherosclerosis is a complex syndrome and, as such, other distinct immune mechanisms and autoimmune responses may also play roles.

Better understandings of the immunopathogenic processes that can cause or contribute to atherosclerosis would have several important ramifications. Facile bioassays could be devised to enable screening of large susceptible populations, as well as expedite more focused and/or frequent clinical surveillance of those individuals at greatest risk. Anti-GRP78aa 246–260 ELISA ODs are already employed as the surrogate end point in an early phase clinical study (NCT03244059). Future uses could also include optimizing the selection of high-risk participants in expensive long-term intervention trials. Perhaps most importantly, many autoimmune diseases are, like COPD, not especially amenable to nonspecific immunosuppressive treatments commonly used in these lung disease patients. In contrast, regimens that target the underlying immunological mechanism(s) (e.g., autoantibodies) are more often beneficial (51–53). The present data, and related reports, provide reason to believe that innovative therapies, focused at one or more critical elements of the causal autoimmune cascade(s), might have unprecedented efficacy for prevention or treatment of these morbid disorders.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • This work was supported by National Institutes of Health Grants K23HL126912 (to D.C.), HL084948 (to F.C.S.), and HL107172 (to S.R.D.).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article:

    CI
    confidence interval
    cIMT
    carotid intima-medial thickness
    COPD
    chronic obstructive pulmonary disease
    CT
    computed tomography
    CVD
    cardiovascular disease
    ECCM
    endothelial cell culture model
    ER
    endoplasmic reticulum
    FEV1
    forced expiratory volume in 1 s
    FVC
    forced vital capacity
    GOLD
    Global Initiative for Chronic Obstructive Lung Disease
    GRP78
    glucose-regulated protein 78
    HAEC
    human aortic endothelial cell
    hs-CRP
    high-sensitivity CRP
    HSP
    heat shock protein
    IRF-7
    IFN regulatory factor-7
    OR
    odds ratio
    pp
    percent predicted
    rGRP78
    recombinant GRP78
    SC
    smoke control
    UPR
    unfolded protein response.

  • Received December 20, 2019.
  • Accepted February 1, 2020.

This article is distributed under the terms of the CC BY 4.0 Unported license.

References

  1. ↵
    Xu, J., S. L. Murphy, K. D. Kochanek, B. Bastian, and E. Arias. 2018. Deaths: final data for 2016. National Vital Statistics Reports 67: 1–76.
  2. ↵
    1. McGarvey L. P.,
    2. M. John,
    3. J. A. Anderson,
    4. M. Zvarich,
    5. R. A. Wise, TORCH Clinical Endpoint Committee
    . 2007. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 62: 411–415.
    OpenUrlAbstract/FREE Full Text
    1. Anthonisen N. R.,
    2. J. E. Connett,
    3. P. L. Enright,
    4. J. Manfreda, Lung Health Study Research Group
    . 2002. Hospitalizations and mortality in the lung health study. Am. J. Respir. Crit. Care Med. 166: 333–339.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Roversi S.,
    2. L. M. Fabbri,
    3. D. D. Sin,
    4. N. M. Hawkins,
    5. A. Agustí
    . 2016. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am. J. Respir. Crit. Care Med. 194: 1319–1336.
    OpenUrl
  5. ↵
    1. Lahousse L.,
    2. H. Tiemeier,
    3. M. A. Ikram,
    4. G. G. Brusselle
    . 2015. Chronic obstructive pulmonary disease and cerebrovascular disease: a comprehensive review. Respir. Med. 109: 1371–1380.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sin D. D.,
    2. L. Wu,
    3. S. F. Man
    . 2005. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 127: 1952–1959.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Sorlie P. D.,
    2. W. B. Kannel,
    3. G. O’Connor
    . 1989. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am. Rev. Respir. Dis. 140: 379–384.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Tamagawa E.,
    2. S. F. van Eeden
    . 2006. Impaired lung function and risk for stroke: role of the systemic inflammation response? Chest 130: 1631–1633.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Feghali-Bostwick C. A.,
    2. A. S. Gadgil,
    3. L. E. Otterbein,
    4. J. M. Pilewski,
    5. M. W. Stoner,
    6. E. Csizmadia,
    7. Y. Zhang,
    8. F. C. Sciurba,
    9. S. R. Duncan
    . 2008. Autoantibodies in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177: 156–163.
    OpenUrlCrossRefPubMed
    1. Núñez B.,
    2. J. Sauleda,
    3. J. M. Antó,
    4. M. R. Julià,
    5. M. Orozco,
    6. E. Monsó,
    7. A. Noguera,
    8. F. P. Gómez,
    9. J. Garcia-Aymerich,
    10. A. Agustí, PAC-COPD Investigators
    . 2011. Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 183: 1025–1031.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Packard T. A.,
    2. Q. Z. Li,
    3. G. P. Cosgrove,
    4. R. P. Bowler,
    5. J. C. Cambier
    . 2013. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol. Res. 55: 48–57.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bon J.,
    2. R. Kahloon,
    3. Y. Zhang,
    4. J. Xue,
    5. C. R. Fuhrman,
    6. J. Tan,
    7. M. Burger,
    8. D. J. Kass,
    9. E. Csizmadia,
    10. L. Otterbein, et al
    . 2014. Autoreactivity to glucose regulated protein 78 links emphysema and osteoporosis in smokers. PLoS One 9: e105066.
  13. ↵
    1. Browning J. L.
    2006. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5: 564–576.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Curtis J. L.,
    2. C. M. Freeman,
    3. J. C. Hogg
    . 2007. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc. Am. Thorac. Soc. 4: 512–521.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Vuga L. J.,
    2. J. R. Tedrow,
    3. K. V. Pandit,
    4. J. Tan,
    5. D. J. Kass,
    6. J. Xue,
    7. D. Chandra,
    8. J. K. Leader,
    9. K. F. Gibson,
    10. N. Kaminski, et al
    . 2014. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 189: 966–974.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Xue J.,
    2. D. J. Kass,
    3. J. Bon,
    4. L. Vuga,
    5. J. Tan,
    6. E. Csizmadia,
    7. L. Otterbein,
    8. M. Soejima,
    9. M. C. Levesque,
    10. K. F. Gibson, et al
    . 2013. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J. Immunol. 191: 2089–2095.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Gonzalez-Gronow M.,
    2. M. A. Selim,
    3. J. Papalas,
    4. S. V. Pizzo
    . 2009. GRP78: a multifunctional receptor on the cell surface. Antioxid. Redox Signal. 11: 2299–2306.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lee A. S.
    2014. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 14: 263–276.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Blumental-Perry A.
    2012. Unfolded protein response in chronic obstructive pulmonary disease: smoking, aging and disease: a SAD trifecta. Curr. Mol. Med. 12: 883–898.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Liu R.,
    2. X. Li,
    3. W. Gao,
    4. Y. Zhou,
    5. S. Wey,
    6. S. K. Mitra,
    7. V. Krasnoperov,
    8. D. Dong,
    9. S. Liu,
    10. D. Li, et al
    . 2013. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin. Cancer Res. 19: 6802–6811.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Misra U. K.,
    2. S. V. Pizzo
    . 2010. Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biol. Ther. 9: 142–152.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Crane E. D.,
    2. A. A. Al-Hashimi,
    3. J. Chen,
    4. E. G. Lynn,
    5. K. D. Won,
    6. Š. Lhoták,
    7. M. Naeim,
    8. K. Platko,
    9. P. Lebeau,
    10. J. H. Byun, et al
    . 2018. Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions. JCI Insight 3: e99363.
  23. ↵
    1. Nezu T.,
    2. N. Hosomi,
    3. S. Aoki,
    4. M. Matsumoto
    . 2016. Carotid intima-media thickness for atherosclerosis. J. Atheroscler. Thromb. 23: 18–31.
    OpenUrlCrossRefPubMed
  24. ↵
    Global Initiative for Chronic Obstructive Lung Disease. 2018. Global strategy for diagnosis, management, and prevention of COPD. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.
  25. ↵
    1. Bon J.,
    2. C. R. Fuhrman,
    3. J. L. Weissfeld,
    4. S. R. Duncan,
    5. R. A. Branch,
    6. C. C. Chang,
    7. Y. Zhang,
    8. J. K. Leader,
    9. D. Gur,
    10. S. L. Greenspan,
    11. F. C. Sciurba
    . 2011. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am. J. Respir. Crit. Care Med. 183: 885–890.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Barr R. G.,
    2. E. A. Berkowitz,
    3. F. Bigazzi,
    4. F. Bode,
    5. J. Bon,
    6. R. P. Bowler,
    7. C. Chiles,
    8. J. D. Crapo,
    9. G. J. Criner,
    10. J. L. Curtis, et al, COPDGene CT Workshop Group
    . 2012. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 9: 151–159.
    OpenUrlCrossRef
  27. ↵
    1. Patibandla P. K.,
    2. A. J. Rogers,
    3. G. A. Giridharan,
    4. M. A. Pallero,
    5. J. E. Murphy-Ullrich,
    6. P. Sethu
    . 2014. Hyperglycemic arterial disturbed flow niche as an in vitro model of atherosclerosis. Anal. Chem. 86: 10948–10954.
    OpenUrl
  28. ↵
    1. Livak K. J.,
    2. T. D. Schmittgen
    . 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) method. Methods 25: 402–408.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Forthal D. N.
    2014. Functions of antibodies. Microbiol. Spectr. 2: 1–17.
    OpenUrl
  30. ↵
    1. Mayadas T. N.,
    2. G. C. Tsokos,
    3. N. Tsuboi
    . 2009. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 120: 2012–2024.
    OpenUrlFREE Full Text
  31. ↵
    1. Gonzalez-Gronow M.,
    2. M. Cuchacovich,
    3. C. Llanos,
    4. C. Urzua,
    5. G. Gawdi,
    6. S. V. Pizzo
    . 2006. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res. 66: 11424–11431.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Foteinos G.,
    2. A. R. Afzal,
    3. K. Mandal,
    4. M. Jahangiri,
    5. Q. Xu
    . 2005. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 112: 1206–1213.
    OpenUrlAbstract/FREE Full Text
    1. Hsue P. Y.,
    2. R. Scherzer,
    3. C. Grunfeld,
    4. J. Imboden,
    5. Y. Wu,
    6. G. Del Puerto,
    7. E. Nitta,
    8. J. Shigenaga,
    9. A. Schnell Heringer,
    10. P. Ganz,
    11. J. Graf
    . 2014. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J. Am. Heart Assoc. 3: e001267.
  34. ↵
    1. Bugała K.,
    2. A. Mazurek,
    3. K. Gryga,
    4. M. Komar,
    5. G. Kopeć,
    6. J. Musiał,
    7. P. Podolec,
    8. C. Perricone,
    9. W. Płazak
    . 2018. Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients. Clin. Rheumatol. 37: 2087–2093.
    OpenUrl
  35. ↵
    1. Estrada R.,
    2. G. A. Giridharan,
    3. M. D. Nguyen,
    4. S. D. Prabhu,
    5. P. Sethu
    . 2011. Microfluidic endothelial cell culture model to replicate disturbed flow conditions seen in atherosclerosis susceptible regions. Biomicrofluidics 5: 32006–3200611.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Kurts C.,
    2. R. M. Sutherland,
    3. G. Davey,
    4. M. Li,
    5. A. M. Lew,
    6. E. Blanas,
    7. F. R. Carbone,
    8. J. F. Miller,
    9. W. R. Heath
    . 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96: 12703–12707.
    OpenUrlAbstract/FREE Full Text
    1. Rush C.,
    2. T. Mitchell,
    3. P. Garside
    . 2002. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J. Immunol. 169: 4951–4960.
    OpenUrlAbstract/FREE Full Text
    1. Martinic M. M.,
    2. C. Huber,
    3. K. Coppieters,
    4. J. E. Oldham,
    5. A. L. Gavin,
    6. M. G. von Herrath
    . 2010. Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis. J. Autoimmun. 35: 404–413.
    OpenUrlCrossRefPubMed
  39. ↵
    1. George T. C.,
    2. J. Bilsborough,
    3. J. L. Viney,
    4. A. M. Norment
    . 2003. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur. J. Immunol. 33: 502–511.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Aksoy M. O.,
    2. V. Kim,
    3. W. D. Cornwell,
    4. T. J. Rogers,
    5. B. Kosmider,
    6. K. Bahmed,
    7. C. Barrero,
    8. S. Merali,
    9. N. Shetty,
    10. S. G. Kelsen
    . 2017. Secretion of the endoplasmic reticulum stress protein, GRP78, into the BALF is increased in cigarette smokers. Respir. Res. 18: 78.
    OpenUrl
  41. ↵
    1. Cusick M. F.,
    2. J. E. Libbey,
    3. R. S. Fujinami
    . 2012. Molecular mimicry as a mechanism of autoimmune disease. Clin. Rev. Allergy Immunol. 42: 102–111.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Rodríguez-Iturbe B.,
    2. R. J. Johnson
    . 2018. Heat shock proteins and cardiovascular disease. Physiol. Int. 105: 19–37.
    OpenUrl
  43. ↵
    1. Srivastava P.
    2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20: 395–425.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Rajaiah R.,
    2. K. D. Moudgil
    . 2009. Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun. Rev. 8: 388–393.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Kirkham P. A.,
    2. P. J. Barnes
    . 2013. Oxidative stress in COPD. Chest 144: 266–273.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Kheradmand F.,
    2. M. Shan,
    3. C. Xu,
    4. D. B. Corry
    . 2012. Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence. Expert Rev. Clin. Immunol. 8: 285–292.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Apostolakis S.,
    2. K. Vogiatzi,
    3. V. Amanatidou,
    4. D. A. Spandidos
    . 2009. Interleukin 8 and cardiovascular disease. Cardiovasc. Res. 84: 353–360.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Gordts P. L. S. M.,
    2. E. M. Foley,
    3. R. Lawrence,
    4. R. Sinha,
    5. C. Lameda-Diaz,
    6. L. Deng,
    7. R. Nock,
    8. C. K. Glass,
    9. A. Erbilgin,
    10. A. J. Lusis, et al
    . 2014. Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metab. 20: 813–826.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Misra U. K.,
    2. S. V. Pizzo
    . 2010. Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of GRP78. Apoptosis 15: 173–182.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Hajian-Tilaki K.
    2013. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J. Intern. Med. 4: 627–635.
    OpenUrlPubMed
  51. ↵
    1. Erickson S. B.,
    2. S. B. Kurtz,
    3. J. V. Donadio Jr.,
    4. K. E. Holley,
    5. C. B. Wilson,
    6. A. A. Pineda
    . 1979. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture’s syndrome. Mayo Clin. Proc. 54: 714–720.
    OpenUrlPubMed
    1. Sem M.,
    2. O. Molberg,
    3. M. B. Lund,
    4. J. T. Gran
    . 2009. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 48: 968–971.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Gelfand E. W.
    2012. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367: 2015–2025.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section